However, therapeutic benefits of TGFβ neutralization are clear in ER- BMET models, as numerous studies have demonstrated significant reductions in osteolytic ER- BMET progression in response to systemic neutralization of TGFβ signaling [31,32], leading to a proposed use of TGFβ-targeting therapeutics in breast cancer BMETs treatment [21,33]. This evidence concerns the gene TGFB1 and breast carcinoma.